
|Articles|December 5, 2012
FDA updated Safety Communication: Ondansetron (Zofran) 32-mg, single IV dose pulled due to potential for serious cardiac risks
The 32-mg, single intravenous dose of the anti-nausea drug Zofran will no longer be marketed because of the potential for serious cardiac risk, according to an updated Safety Communication from FDA.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
Study Links Corticosteroid Use With Long COVID Symptoms
2
FDA Accepts Sandoz Applications for Generic Tirzepatide
3
Advocacy in Action: How Community Pharmacists Can Drive Change
4
Rezdiffra Reduces Cardiovascular, Liver-Related Risk Markers in MASH
5































